MURALI VEERAMACHANENI: Open Payments
NPI 1851374367 · AMARILLO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,166 in 55 payments from 13 companies in 2025. Trend: 2023 $895 · 2024 $865 · 2025 $1,166
Food & beverage: $1,166
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 9 | $177 |
| Collegium Pharmaceutical, Inc. | 9 | $153 |
| Supernus Pharmaceuticals, Inc. | 5 | $108 |
| Alkermes, Inc. | 5 | $107 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $107 |
| Otsuka America Pharmaceutical, Inc. | 4 | $102 |
| E.R. Squibb & Sons, L.L.C. | 4 | $100 |
| Teva Pharmaceuticals USA, Inc. | 4 | $82 |
| Lundbeck LLC | 3 | $76 |
| ABBVIE INC. | 3 | $64 |
Products named: INGREZZA, Jornay PM, REXULTI, Qelbree, ARISTADA, CAPLYTA, COBENFY, AUSTEDO XR.
Industry payments across TX — which companies pay providers there.
